Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension

References

• Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science 1991;254:1178-81
   PubMed Web of Science ®Google Scholar
• Graefe AV. Ueber die Iridektomie beim Glaukom und ueber den glaukomatösen Prozess. Arch Ophthalmol 1857;3:470
   Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498-505
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79
   PubMed Web of Science ®Google Scholar
• The AGIS Investigators.The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• Van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-85
   PubMed Web of Science ®Google Scholar
• Park HY, Lee NY, Kim JH, Park CK. Intraocular pressure lowering, change of antiapoptotic molecule expression, and neuroretinal changes by dorzolamide 2%/timolol 0.5% combination in a chronic ocular hypertension rat model. J Ocul Pharmacol Ther 2008;24:563-71
   PubMed Web of Science ®Google Scholar
• Zanon-Moreno V, Garcia-Medina JJ, Gallego-Pinazo R et al.Antioxidant status modifications by topical administration of dorzolamide in primary open-angle glaucoma. Eur J Ophthalmol 2009;19:565-71
   PubMed Web of Science ®Google Scholar
• Gasser P, Flammer J. Influence of vasospasm on visual function. Doc Ophthalmol 1987;66:3-18
   PubMed Web of Science ®Google Scholar
• Pillunat LE, Lang GK, Harris A. The visual response to increased ocular blood flow in normal pressure glaucoma. Surv Ophthalmol 1994;38(Suppl.):S139-47
   PubMedGoogle Scholar
• Sugrue M, Harris A, Adamsons I. Dorzolamide hydrochloride: a topically active carbonic anhydrase inhibitor for the treatment of glaucoma. Drugs Today 1997;33:283-98
   Web of Science ®Google Scholar
• Schmitz K, Banditt P, Motschmann M, et al. Population pharmacokinetics of 2% topical dorzolamide in the aqueous humor of humans. Invest Ophthalmol Vis Sci 1999;40:1621-4
   PubMed Web of Science ®Google Scholar
• Rassam SM, Patel V, Kohner EM. The effect of acetazolamide on the retinal circulation. Eye 1993;7:697-702
   PubMed Web of Science ®Google Scholar
• Taki K, Kato H, Endo S, et al. Cascade of acetazolamide-induced vasodilatation. Res Commun Mol Pathol Pharmacol 1999;103:240-8
   PubMed Web of Science ®Google Scholar
• Friberg L, Kastrup J, Rizzi D, et al. Cerebral blood flow and end-tidal pCO2 during prolonged acetazolamide treatment in humans. Am J Physiol 1990;258:H954-9
   PubMed Web of Science ®Google Scholar
• Josefsson A, Sigurdsson SB, Bang K, et al. Dorzolamide induces vasodilatation in isolated pre-contracted bovine retinal arteries. Exp Eye Res 2004;78:215-21
   PubMed Web of Science ®Google Scholar
• Torring MS, Holmgaard K, Hessellund A, et al. The vasodilating effect of acetazolamide and dorzolamide involves mechanisms other than carbonic anhydrase inhibition. Invest Ophthalmol Vis Sci 2009;50:345-51
   PubMed Web of Science ®Google Scholar
• Friedman E, Chandra SR. Choroidal blood flow. 3. Effects of oxygen and carbon dioxide. Arch Ophthalmol 1972;87:70-1
   PubMed Web of Science ®Google Scholar
• Riva CE, Cranstoun SD, Grunwald JE, et al. Choroidal blood flow in the foveal region of the human ocular fundus. Invest Ophthalmol Vis Sci 1994;35:4273-81
   PubMed Web of Science ®Google Scholar
• Schmetterer L, Wolzt M, Lexer F, et al. The effect of hyperoxia and hypercapnia on fundus pulsations in the macular and optic disc region in healthy young men. Exp Eye Res 1995;61:685-90
   PubMed Web of Science ®Google Scholar
• Hageman GS, Zhu XL, Waheed A, et al. Localization of carbonic anhydrase IV in a specific capillary bed of the human eye. Proc Natl Acad Sci USA 1991;88:2716-20
   PubMed Web of Science ®Google Scholar
• Sender S, Gros G, Waheed A, et al. Immunohistochemical localization of carbonic anhydrase IV in capillaries of rat and human skeletal muscle. J Histochem Cytochem 1994;42:1229-36
   PubMed Web of Science ®Google Scholar
• Kehler AK, Holmgaard K, Hessellund A, et al. Variable involvement of the perivascular retinal tissue in carbonic anhydrase inhibitor induced relaxation of porcine retinal arterioles in vitro. Invest Ophthalmol Vis Sci 2007;48:4688-93
   PubMed Web of Science ®Google Scholar
• Inoue J, Oka M, Aoyama Y, et al. Effects of dorzolamide hydrochloride on ocular tissues. J Ocul Pharmacol Ther 2004;20:1-13
   PubMed Web of Science ®Google Scholar
• Nagelhus EA, Mathiisen TM, Bateman AC, et al. Carbonic anhydrase XIV is enriched in specific membrane domains of retinal pigment epithelium, Muller cells, and astrocytes. Proc Natl Acad Sci USA 2005;102:8030-5
   PubMed Web of Science ®Google Scholar
• Olander KW, Galet VA, Jia G, et al. Relationship between visual field severity and response to fixed combination dorzolamide/timolol or timolol alone. J Ocul Pharmacol Ther 2009;25:357-64
   PubMed Web of Science ®Google Scholar
• Kaup M, Plange N, Niegel M, et al. Effects of brinzolamide on ocular haemodynamics in healthy volunteers. Br J Ophthalmol 2004;88:257-62
   PubMed Web of Science ®Google Scholar
• Miglior S, Zeyen T, Pfeiffer N, et al. Results of the European Glaucoma Prevention Study. Ophthalmology 2005;112:366-75
   PubMed Web of Science ®Google Scholar
• Strahlman E, Tipping R, Vogel R. A six-week dose–response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose–Response Study Group. Am J Ophthalmol 1996;122:183-94
   PubMed Web of Science ®Google Scholar
• Quigley HA. European Glaucoma Prevention Study. Ophthalmology 2005;112:1642-3
   PubMed Web of Science ®Google Scholar
• Parrish RK 2nd. The European Glaucoma Prevention Study and the Ocular Hypertension Treatment Study: why do two studies have different results?. Curr Opin Ophthalmol 2006;17:138-41
   PubMed Web of Science ®Google Scholar
• Martinez A, Sanchez-Salorio M. A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients. J Ocul Pharmacol Ther 2009;25:239-48
   PubMed Web of Science ®Google Scholar
• Martinez A, Sanchez M. Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma. Acta Ophthalmol 2009 Oct [Epub ahead of print]
   Google Scholar
• Flammer J, Haefliger IO, Orgul S, et al. Vascular dysregulation: a principal risk factor for glaucomatous damage?. J Glaucoma 1999;8:212-19
   PubMed Web of Science ®Google Scholar
• Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20
   PubMed Web of Science ®Google Scholar
• Siesky B, Harris A, Brizendine E, et al. Literature review and meta-analysis of topical carbonic anhydrase inhibitors and ocular blood flow. Surv Ophthalmol 2009;54:33-46
   PubMed Web of Science ®Google Scholar
• Martinez A, Sanchez M. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study. Clin Ther 2008;30:1120-34
   PubMed Web of Science ®Google Scholar
• Asman P, Heijl A. Glaucoma Hemifield Test. Automated visual field evaluation. Arch Ophthalmol 1992;110:812-19
   PubMed Web of Science ®Google Scholar
• Chen PP, Bhandari A. Fellow eye prognosis in patients with severe visual field loss in 1 eye from chronic open-angle glaucoma. Arch Ophthalmol 2000;118:473-8
   PubMed Web of Science ®Google Scholar
• Nouri-Mahdavi K, Hoffman D, Gaasterland D, et al. Prediction of visual field progression in glaucoma. Invest Ophthalmol Vis Sci 2004;45:4346-51
   PubMed Web of Science ®Google Scholar
• O’Brien C, Schwartz B, Takamoto T, et al. Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma. Am J Ophthalmol 1991;111:491-500
   PubMed Web of Science ®Google Scholar
• Katz J, Gilbert D, Quigley HA, et al. Estimating progression of visual field loss in glaucoma. Ophthalmology 1997;104:1017-25
   PubMed Web of Science ®Google Scholar
• Dong J, Chihara E. Slope analysis of the optic disc in eyes with ocular hypertension and early normal tension glaucoma by confocal scanning laser ophthalmoscope. Br J Ophthalmol 2001;85:56-62
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007;114:1965-72
   PubMed Web of Science ®Google Scholar
• Heijl A, Bengtsson B, Chauhan BC, et al. A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmology 2008;115:1557-65
   PubMed Web of Science ®Google Scholar
• Polska E, Kircher K, Ehrlich P, et al. RI in central retinal artery as assessed by CDI does not correspond to retinal vascular resistance. Am J Physiol Heart Circ Physiol 2001;280:H1442-7
   PubMed Web of Science ®Google Scholar
• Galassi F, Sodi A, Ucci F, et al. Ocular hemodynamics and glaucoma prognosis: a color Doppler imaging study. Arch Ophthalmol 2003;121:1711-15
   PubMed Web of Science ®Google Scholar
• Satilmis M, Orgul S, Doubler B, Flammer J. Rate of progression of glaucoma correlates with retrobulbar circulation and intraocular pressure. Am J Ophthalmol 2003;135:664-9
   PubMed Web of Science ®Google Scholar
• Zeitz O, Galambos P, Wagenfeld L, et al. Glaucoma progression is associated with decreased blood flow velocities in the short posterior ciliary artery. Br J Ophthalmol 2006;90:1245-8
   PubMed Web of Science ®Google Scholar
• Martinez A, Sanchez M. Predictive value of colour Doppler imaging in a prospective study of visual field progression in primary open-angle glaucoma. Acta Ophthalmol Scand 2005;83:716-22
   PubMedGoogle Scholar
• Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004;15:132-5
   PubMedGoogle Scholar
• Stewart WC, Kruft B, Nelson LA, et al. Ophthalmologist attitudes regarding fixed combination treatment for glaucoma in the European Union. Eur J Ophthalmol 2009;19:588-93
   PubMed Web of Science ®Google Scholar
• Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retinal Eye Res 2000;19:87-112
   PubMed Web of Science ®Google Scholar
• Stams T, Chen Y, Boriack-Sjodin PA, et al. Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: molecular basis of isozyme-drug discrimination. Protein Sci 1998;7:556-63
   PubMed Web of Science ®Google Scholar
• Siesky B, Harris A, Cantor LB, et al. A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma. Br J Ophthalmol 2008;92:500-4
   PubMed Web of Science ®Google Scholar
• Costagliola C, Campa C, Parmeggiani F, et al. Effect of 2% dorzolamide on retinal blood flow: a study on juvenile primary open-angle glaucoma patients already receiving 0.5% timolol. Br J Clin Pharmacol 2007;63:376-9
   PubMed Web of Science ®Google Scholar
• Chiselita D, Antohi I, Medvichi R, et al. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol–dorzolamide; a prospective, randomized, masked, cross-over design study. Oftalmologia 2005;49:39-45
   PubMedGoogle Scholar
• Fuchsjäger-Mayrl G, Wally B, Rainer G, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol 2005;89:1293-7
   PubMed Web of Science ®Google Scholar
• Fuchsjäger-Mayrl G, Georgopoulos M, Hommer A, et al. Effect of dorzolamide and timolol on ocular pressure – blood flow relationship in patients with primary open angle glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci 2010;51:1289-96
   Google Scholar
• Bernd AS, Pillunat LE, Bohm AG, et al. [Ocular hemodynamics and visual field in glaucoma treated with dorzolamide]. Ophthalmologe 2001;98:451-5
   PubMed Web of Science ®Google Scholar
• Strohmaier K, Snyder E, DuBiner H, et al. The efficacy and safety of the dorzolamide–timolol combination versus the concomitant administration of its components. Ophthalmology 1999;106:1-9
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Airaksinen PJ, Getson AJ, et al. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (Cosopt) versus 0.005% (Xalatan) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004;82:42-8
   PubMedGoogle Scholar
• Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol 1995;113:1009-16
   PubMed Web of Science ®Google Scholar
• Heijl A, Strahlman E, Sverrisson T, et al. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. Ophthalmology 1997;104:137-42
   PubMed Web of Science ®Google Scholar
• Kaback M, Scoper SV, Arzeno G, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology 2008;115:1728-34
   PubMed Web of Science ®Google Scholar
• Day DG, Hollander DA. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr Med Res Opin 2008;24:1435-42
   PubMed Web of Science ®Google Scholar
• Shoji N, Ogata H, Suyama H, et al. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin 2005;21:503-8
   PubMed Web of Science ®Google Scholar
• Michaud JE, Friren B. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:235-43
   PubMed Web of Science ®Google Scholar
• Shin D. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol 2000;44(Suppl. 2):S163-8
   PubMedGoogle Scholar
• Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol 1998;126:400-8
   PubMed Web of Science ®Google Scholar